Northeast Florida Equestrian Society Joins NVBDC MVO Task Force to Expand Equine-Assisted Services for Veterans
Northeast Florida Equestrian Society/H.O.R.S.E. Therapies Joins NVBDC MVO Task Force to Expand Equine-Assisted Services for Veterans
DETROIT, MI, UNITED STATES, February 14, 2025 / EINPresswire.com / -- The National Veteran Business Development Council (NVBDC) proudly welcomes Northeast Florida Equestrian Society (NFES) and its H.O.R.S.E. Therapies program as the newest member of its Military and Veteran Organization (MVO) Task Force. Dedicated to harnessing the healing power of horses, NFES provides equine-assisted services to veterans, active-duty service members, and individuals with physical and emotional challenges, fostering rehabilitation, resilience, and community connection.
'As someone who has personally experienced the transformative power of horses, I am honored to be part of an organization that brings this healing to others—especially our nation's veterans,' said Ashton Kroner, Director of Development & Strategic Partnerships at NFES. 'Joining the NVBDC MVO Task Force allows us to expand our reach, collaborate with veteran-owned businesses, and strengthen our commitment to those who have served.'
NFES manages the Jacksonville Equestrian Center through a contract with the City of Jacksonville, Florida, hosting more than 45 events annually to support its H.O.R.S.E. Therapies program. With a focus on inclusivity and healing, NFES offers adaptive equine-assisted services tailored to veterans coping with physical injuries, PTSD, and other service-related challenges.
Through its flagship Veterans Equine Camp, NFES provides military veterans with immersive therapeutic experiences designed to promote well-being and personal growth. Additionally, the organization prioritizes veteran employment, creating opportunities for former service members to transition into meaningful civilian careers within the equestrian community.
A Legacy of Impact and Community Support
NFES has a longstanding history of serving the community, including offering emergency shelter to over 600 horses during Florida's recent hurricanes. The organization's ability to provide vital support in times of crisis further cements its role as a trusted resource for both veterans and the equestrian community.
Horses and Heroes Rodeo: A Commitment to Giving Back
One of NFES's most significant annual events, the Horses and Heroes Rodeo, will take place on October 24-25, 2025. Now in its third year, the rodeo directly benefits veterans and first responders, with proceeds supporting the UF Health Haley Brain Wellness Program for traumatic brain injury (TBI) treatment and funding for the H.O.R.S.E. Therapies program.
'We believe that healing takes many forms, and through this event, we not only raise critical funds but also foster a deeper sense of connection between veterans, first responders, and the broader community,' Kroner added.
How to Support NFES and H.O.R.S.E. Therapies
NFES welcomes corporate partnerships, sponsorships, and volunteers to help further its mission. With over 90,000 visitors annually at the Jacksonville Equestrian Center, the organization provides a unique platform for veteran-owned businesses to showcase their services while making a lasting impact. To learn more about how to get involved, visit jaxhorsetherapies.org/nfes or contact Ashton Kroner at [email protected].
About the National Veteran Business Development Council (NVBDC)
The National Veteran Business Development Council (NVBDC) is the leading third-party certification organization for veteran-owned businesses of all sizes. NVBDC connects certified veteran-owned businesses with supplier diversity programs in major corporations, fostering growth and success for veteran entrepreneurs. Additional information can be found at nvbdc.org.
About the NVBDC's Military & Veteran Organization (MVO) Task Force
NVBDC's MVO Task Force enables NVBDC to collaborate resources with task force partners to increase awareness and establish a respected position in the industry supporting veteran business success. Additional information can be found at nvbdctaskforce.org.
(586) 665-9020
[email protected]
MVO Task Force Contact:
Kathy Poynton
(703) 282-6862
[email protected]
Keith King, Founder & CEO
National Veteran Business Development Council
+1 313-446-6885
email us here
Visit us on social media:
X
LinkedIn
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
OKC VA preps for emergency operation exercise June 9
OKLAHOMA CITY (KFOR) – Officials with the Oklahoma City VA Medical Center announced on Friday an Emergency Operations Exercise is set to be conducted on June 9th. According to VA officials, the exercise operation will begin at 9:00 a.m. providing real life incidents ensuring mocking procedures are followed while providing help in the event of a mass casualty incident. 'This exercise will test the response capabilities of the OKC VA Medical Center Staff to a mass casualty event,' said Christopher Ence, Emergency Management Specialist. Service Oklahoma warns residents of text scam The VA says there will be no interruption to services during the exercise and if Veterans should not step in if they see staff participating. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Health Line
9 hours ago
- Health Line
CHAMPVA and Medicare: Which Is Primary?
You can use CHAMPVA and Medicare at the same time. When you use Medicare together with CHAMPVA, Medicare is the primary payer. CHAMPVA is a cost-sharing health coverage program for some military families who don't qualify for TRICARE. You can use CHAMPVA with Medicare when you're eligible for both programs. CHAMPA will be the secondary payer to Medicare and will pay most of your out-of-pocket costs. Since there are no additional premiums if you qualify for CHAMPVA, using it alongside Medicare can significantly lower your healthcare costs. Glossary of common Medicare terms Out-of-pocket cost: This is the amount you pay for care when Medicare doesn't pay the full cost or offer coverage. It includes premiums, deductibles, coinsurance, and copayments. Premium: This is the monthly amount you pay for Medicare coverage. Deductible: This is the annual amount you must spend out of pocket before Medicare begins to cover services and treatments. Coinsurance: This is the percentage of treatment costs you're responsible for paying out of pocket. With Medicare Part B, you typically pay 20%. Copayment: This is a fixed dollar amount you pay when receiving certain treatments or services. With Medicare, this often applies to prescription medications. What is CHAMPVA? The Civilian Health and Medical Program of the Department of Veterans Affairs (CHAMPVA) is a healthcare plan for certain dependents of veterans. CHAMPVA is a different program from TRICARE, which also services military members, veterans, and their families. TRICARE eligibility is open to people who are: active or retired uniformed service members spouses or children of active or retired uniformed service members members of the Army National Guard or Reserve spouses or children of Army National Guard or Reserve members spouses or children of deceased military members certain former spouses of military members Medal of Honor recipients spouses and children of Medal of Honor recipients You can't use CHAMPVA if you have or are eligible for TRICARE. CHAMPVA helps cover certain dependents who aren't eligible for TRICARE. For example, service members who leave active duty under certain conditions might not qualify for TRICARE. However, if they have a disability caused by their service, their family may be able to enroll in CHAMPVA. How does CHAMPVA work with Medicare? Since 2001, CHAMPVA beneficiaries have been able to use their coverage after turning 65 years old. This means CHAMPVA can be used alongside Medicare. You'll need to be enrolled in Medicare to keep your CHAMPVA coverage. Here are the rules for how that works: If you turned age 65 before June 5, 2001, and did not have Medicare Part B at the time, you only need to be enrolled in Medicare Part A to keep your CHAMPVA coverage. If you turned age 65 before June 5, 2001, and were already enrolled in Part B at that time, you need to be enrolled in both Part A and Part B to keep your CHAMPVA coverage. If you turned 65 years old after June 5, 2001, you need to be enrolled in parts A and B to keep your CHAMPVA coverage. Example For example, let's say you turned 65 years old in 1999 and enrolled in Medicare parts A and B. You won't be able to drop your Part B coverage and keep your CHAMPVA coverage. However, if you turned age 65 in 1999 and enrolled in only Part A, you wouldn't need to sign up for Part B to keep your CHAMPVA coverage. You can use CHAMPVA alongside: Original Medicare (parts A and B) Medicare Advantage (Part C) Medicare Part D, which is prescription drug coverage It's important to note that CHAMPVA won't pay for the cost of your Part B premium. You should also know that you can no longer use VA healthcare facilities or healthcare professionals once you're enrolled in Medicare. What services does CHAMPVA cover? CHAMPVA is a cost-sharing health insurance program. This means it will pay a portion of the cost of health services you receive, and you'll pay the remaining amount. You won't pay a premium for CHAMPVA, but there is a $50 deductible before coverage kicks in. After you pay your deductible, CHAMPVA will pay what's known as the 'allowable amount' for all covered services. Generally, CHAMPVA will pay 75% of the allowable amount, and you'll pay the other 25%. Covered services include: hospital stays primary care doctor visits specialist visits lab work skilled nursing care home care ambulance transportation mental health services prescription drugs There are two other completely covered benefits: Hospice care from any provider is 100% covered under CHAMPVA. You can also get prescription coverage at no cost to you if you use the Department of Veterans Affairs (VA) Meds by Mail program, if you have no other prescription drug coverage. Coverage works differently if you use CHAMPVA alongside another health insurance plan, including Medicare. When you use CHAMPVA with another insurance plan, CHAMPVA becomes what's called a secondary payer. This means your other insurance plan will be billed first, and CHAMPVA will then pay the remaining cost. This can save you a lot of money on out-of-pocket medical expenses like copayments or coinsurance amounts. Who pays first for healthcare costs? Medicare is the primary payer when you use it with CHAMPVA. This means Medicare will be the first to pay the cost of any service you receive, and then CHAMPVA will pay the rest. You'll have very few out-of-pocket costs using CHAMPVA and Medicare together since CHAMPVA will generally pay any copayments or coinsurance amounts. You can expect to pay: nothing out of pocket for any service that both Medicare and CHAMPVA cover your Medicare coinsurance cost of 20% for a service Medicare covers, but CHAMPVA doesn't your CHAMPVA cost sharing of 25% for anything CHAMPVA covers, but Medicare doesn't The same rules apply to Medicare Part D. CHAMPVA will pick up your copayments on all covered prescriptions. It will also pay 75% of the cost of prescriptions that your Medicare Part D plan doesn't cover. Present both your Medicare Part D plan card and your CHAMPVA ID card at your in-network pharmacy for coverage. Getting your coverage questions answered If you're not sure who will pay for a service, you can check ahead of time by: calling Medicare's Benefits Coordination & Recovery Center at 855-798-2627 (TTY: 855-797-2627) calling CHAMPVA customer care at 800-733-8387, Monday through Friday from 8:05 a.m. to 7:30 p.m. Eastern Standard Time What about Medicare Advantage? You can use your CHAMPVA coverage with a Medicare Advantage plan. Since Medicare Advantage plans replace Original Medicare, having an Advantage plan still meets the requirement to be enrolled in Medicare to keep CHAMPVA once you're age 65. Your Medicare Advantage plan will be the primary payer, just like when you have Original Medicare. CHAMPVA will pay your copayments and other out-of-pocket costs. Your bill will go to your Medicare Advantage plan first and then to CHAMPVA. In most cases, you won't have any out-of-pocket costs. Many Medicare Advantage plans also include Part D coverage. When you use a Medicare Advantage plan that includes Part D along with CHAMPVA, your CHAMPVA benefits will pick up the cost of your prescription copayments. Medicare Advantage plans often have networks. The network includes all the providers that your Medicare Advantage plan will cover healthcare services. In many cases, you'll need to pay out of pocket for any services you receive from an out-of-network provider. However, when you use CHAMPVA along with your Medicare Advantage plan, you can often get 75% of the cost of out-of-network services covered. How do I choose the right coverage options for me? You need to enroll in Original Medicare (parts A and B) to keep your CHAMPVA coverage. You can also choose to enroll in additional Medicare parts, such as: Medicare Advantage Medigap Medicare Part D The best option for you will depend on your personal needs and budget. Medicare Advantage, Medigap, and Medicare Part D plans have their own premiums, deductibles, and other costs. CHAMPVA can cover some of these costs, but not your premiums. You might not even need additional Medicare parts if you're using CHAMPVA. For example, Medigap plans are designed to cover the out-of-pocket costs of Medicare parts A and B. However, since CHAMPVA already does this when you use it alongside Medicare, you might not need a Medigap plan. Here are some other common scenarios to consider: Original Medicare + CHAMPVA Let's say you have CHAMPVA and Medicare parts A and B, and you choose not to enroll in any other Medicare plans. You'd pay the Medicare Part B premium, and Medicare would be your primary payer for all covered services. You could get prescriptions for 25% of the allowable amount at a pharmacy or completely covered if you use the Meds by Mail program using only CHAMPVA. Original Medicare + Part D + CHAMPVA You have CHAMPVA, Medicare parts A and B, and a Part D plan. You'd pay the Medicare Part B premium and the premium for your Part D plan. Medicare would be the primary payer for services and prescriptions. CHAMPVA would pick up your copayments and coinsurance amounts. Medicare Advantage + CHAMPVA You have CHAMPVA and a Medicare Advantage plan that includes Part D coverage. You'd pay the Medicare Part B premium plus the premium for your Medicare Advantage plan. Medicare would be the primary payer for your services and prescriptions. CHAMPVA would pay your copayments and coinsurance. Ways to save on Medicare coverage It's worth noting that you may be able to find Medicare Advantage or Medigap plans in your area with $0 premiums. You can shop for plans in your area on the Medicare website and compare prices, networks, and covered services before you commit to a plan. You can also look for savings on your Medicare coverage. You might qualify for programs to help lower your costs if you have a limited income. These programs include: Extra Help, which lowers your prescription drug costs Medicare savings programs, which can lower your costs for parts A and B Ultimately, the right plan for you depends on your needs and your budget. You'll want to select a plan that includes: the doctors you want to see any prescriptions you take any services you need You can also search for premiums in your price range, and those with out-of-pocket costs you can manage. How do I know if I'm eligible for CHAMPVA? You're eligible for CHAMPVA if you're the dependent child or the current or widowed spouse of a veteran who meets one of these conditions: is permanently and totally disabled from a service-related injury or disability was permanently and totally disabled from a service-related injury or disability at the time of their death died from service-related injury or disability died during active duty is not eligible for TRICARE There is no premium cost for CHAMPVA coverage. You can apply for CHAMPVA at any time. You'll need to send in an application along with documents that prove your eligibility. Depending on your circumstances, these might include: service records marriage records birth certificates You'll also need to send in information about any other insurance plan you currently have. Your application will generally be processed in 3 to 6 weeks. If your application is approved, you will receive a CHAMPVA card in the mail. As soon as your card arrives, you can start using CHAMPVA coverage. The takeaway When you use CHAMPVA with Medicare, CHAMPVA acts as the secondary payer. CHAMPVA doesn't cover Medicare premiums but will cover most of your other out-of-pocket healthcare expenses. CHAMPVA pays 75% of the cost of most services. The information on this website may assist you in making personal decisions about insurance, but it is not intended to provide advice regarding the purchase or use of any insurance or insurance products. Healthline Media does not transact the business of insurance in any manner and is not licensed as an insurance company or producer in any U.S. jurisdiction. Healthline Media does not recommend or endorse any third parties that may transact the business of insurance.
Business Wire
2 days ago
- Business Wire
Seyltx Expands GluN2B Antagonist Pipeline with Clinical-Stage and Small-Molecule Candidates for Chronic Cough
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seyltx, Inc., ('Seyltx', 'Company') a clinical-stage biotherapeutics company focused on developing therapies to treat chronic cough, today announced it has entered into an option agreement with NeurOp, Inc. ('NeurOp'') for a portfolio of novel GluN2B antagonists. This agreement provides Seyltx with an option to worldwide, exclusive rights to develop and commercialize a portfolio of GluN2B negative allosteric modulators (NAMs) for treating chronic cough in humans, including in refractory chronic cough (RCC) and chronic cough associated with Idiopathic Pulmonary Fibrosis (IPF-Cough). "We are incredibly excited about this option agreement with NeurOp, which significantly strengthens our pipeline for chronic cough therapies," said Dr. Dietrich A. Stephan, Seyltx's CEO. This strategic agreement combines Seyltx's expertise in chronic cough therapeutic development with NeurOp's expertise in NMDA receptor biology and innovative GluN2B inhibitors. This combination complements and deepens Seyltx's ongoing development of Ifenprodil, a potent NMDA antagonist that is highly selective towards the GluN2B subunit, currently in Phase 2 development. The combined effort is expected to accelerate the development and commercialization of new therapies for chronic cough and solidify Seyltx's position as a leader in addressing this significant unmet medical need. The option agreement includes 8 novel compounds, including NP10679, which has completed Phase 1 and provides Seyltx with a second clinical-phase candidate, with the potential to provide differentiated performance compared to Ifenprodil. These compounds have excellent potency, selectivity, pharmacokinetics, solubility, and metabolism. Strong intellectual property exists across all optioned compounds. "We are incredibly excited about this option agreement with NeurOp, which significantly strengthens our pipeline for chronic cough therapies," said Dr. Dietrich A. Stephan, Seyltx's CEO. "Refractory chronic cough impacts approximately 6 million people in the USA alone, representing a substantial unmet medical need. Furthermore, chronic cough associated with IPF, an orphan condition affecting up to 140,000 people in the US, is a primary driver of deteriorated quality of life for these patients. Our agreement with NeurOp for advanced GluN2B NAMs, particularly NP10679, offers a promising avenue to provide potentially superior treatment options to these patients by addressing the condition with a centrally acting non-narcotic solution." Dr. James McNamara, Executive Chairman of NeurOp added, "NeurOp has been dedicated to advancing novel GluN2B-targeted therapies. This agreement with Seyltx is a testament to the sophistication of our team's expertise in the NMDA receptor biology and the development of our GluN2B antagonists. Seyltx's deep understanding and focus on chronic cough make them an ideal partner to further develop and bring these important compounds to patients in need. We look forward to a very productive partnership." NMDA is a validated therapeutic target in cough, with the only FDA-approved cough therapy being a non-specific NMDA antagonist. Preclinical research has identified the GluN2B subunit of NMDA as a primary target for cough suppression. Traditional non-specific NMDA antagonists have demonstrated limited efficacy due to dose limiting side effects. However, specifically targeting the GluN2B subunit, provides the potential to achieve robust cough suppression, while avoiding the adverse event profile observed with non-specific NMDA antagonists. The addition of NP10679 to the portfolio provides the opportunity to effectively engage the GluN2B receptor, below the safety threshold established in Phase 1, while offering a differentiated selectivity and efficacy profile compared to Ifenprodil. The option agreement has been approved by the management of both companies with a conversion to an exclusive world-wide license agreement anticipated within 12 months. About Seyltx: Seyltx ( is a clinical stage biotherapeutics company focused on developing innovative therapies to treat chronic cough and other neuronal hypersensitivity indications. Its lead indication is refractory chronic cough, a significant unmet medical need, with a follow-on opportunity in chronic cough associated with Idiopathic Pulmonary Fibrosis (IPF-Cough). Seyltx's lead compound is Ifenprodil, an NMDA receptor inhibitor highly selective towards the GluN2B subunit, which has completed a Phase 2a trial in chronic cough associated with IPF, with statistically significant reductions in cough from baseline at 12-weeks, and statistically significant improvements on all patient reported outcomes employed. Seyltx is currently progressing into Phase 2 crossover trials. About NeurOp: NeurOp, Inc. is a privately held, clinical-stage biopharmaceutical company based in Atlanta, Georgia that is developing small-molecule therapies for central nervous system disorders, including severe pain, treatment-resistant depression, subarachnoid hemorrhage (SAH) and stroke. Its proprietary compounds selectively inhibit the GluN2B subunit of neuronal NMDA receptors and are designed for potential therapeutic benefit with an improved safety and tolerability profile relative to other NMDA receptor antagonists. Forward-Looking Statements: Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute "forward-looking statements" within the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'potential,' 'possible,' 'projects,' 'plans,' and similar expressions. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown, many of which are beyond Seyltx's control.
